Global law firm White & Case LLP has advised Carnegie, DNB Markets, Jefferies, Cowen and Kempen & Co, as joint bookrunners, on the completed SEK 1.414 billion (approximately US$144 million) directed share issue by Oncopeptides.
The Oncopeptides board of directors agreed the directed share issue of 12,295,000 new shares at a subscription price of SEK 115 per share. The company will receive gross proceeds of approximately SEK 1.414 billion.
Established in 2000 and based in Stockholm, Sweden, Oncopeptides is a pharmaceutical company which develops drugs for the treatment of cancer.
The White & Case team which advised on the transaction was led by partner Rikard Stenberg (Stockholm) and included partner Mikko Hulkko (Helsinki) and associate Christoffer Nilmen (Stockholm).
For more information, please speak to your local media contact.